Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040

Stock Information for Anixa Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Anixa Biosciences Inc.

Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board
Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026
Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy
Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology
Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.